Efficacy of Perifosine Alone and in Combination With Dexamethasone for Patients With Multiple Myeloma
Status:
Completed
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
This is a phase 2 study of perifosine in patients with multiple myeloma. Patients will
receive perifosine 150 mg at bedtime (qhs) daily. Patients will be assessed by serum and/or
urine-electrophoresis at least every 3 weeks.